- Home
- MTR vs BRTX Comparison
MTR vs BRTX Comparison
Compare MTR & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTR
- BRTX
- Stock Information
- Founded
- MTR 1979
- BRTX 1997
- Country
- MTR United States
- BRTX United States
- Employees
- MTR N/A
- BRTX N/A
- Industry
- MTR Oil & Gas Production
- BRTX Managed Health Care
- Sector
- MTR Energy
- BRTX Health Care
- Exchange
- MTR Nasdaq
- BRTX Nasdaq
- Market Cap
- MTR 11.8M
- BRTX 11.3M
- IPO Year
- MTR N/A
- BRTX N/A
- Fundamental
- Price
- MTR $6.33
- BRTX $1.41
- Analyst Decision
- MTR
- BRTX Strong Buy
- Analyst Count
- MTR 0
- BRTX 1
- Target Price
- MTR N/A
- BRTX $18.00
- AVG Volume (30 Days)
- MTR 14.1K
- BRTX 100.5K
- Earning Date
- MTR 01-01-0001
- BRTX 11-12-2024
- Dividend Yield
- MTR 3.56%
- BRTX N/A
- EPS Growth
- MTR N/A
- BRTX N/A
- EPS
- MTR 0.35
- BRTX N/A
- Revenue
- MTR $966,169.00
- BRTX $377,000.00
- Revenue This Year
- MTR N/A
- BRTX $482.76
- Revenue Next Year
- MTR N/A
- BRTX $212.24
- P/E Ratio
- MTR $18.20
- BRTX N/A
- Revenue Growth
- MTR N/A
- BRTX 189.55
- 52 Week Low
- MTR $5.60
- BRTX $1.03
- 52 Week High
- MTR $14.49
- BRTX $3.67
- Technical
- Relative Strength Index (RSI)
- MTR 43.26
- BRTX 41.13
- Support Level
- MTR $6.06
- BRTX $1.40
- Resistance Level
- MTR $6.79
- BRTX $1.60
- Average True Range (ATR)
- MTR 0.31
- BRTX 0.10
- MACD
- MTR -0.10
- BRTX 0.00
- Stochastic Oscillator
- MTR 20.77
- BRTX 42.86
About MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.